North America and Europe Age-Related Macular Degeneration Therapeutics Market- Drivers
North America & Europe Age-Related Macular Degeneration Therapeutics Market: Restraints
High cost of treatment
The high cost of treatment is expected to hamper the North America & Europe age-related macular degeneration therapeutics market growth. For instance, according to an article published by the Biomolecules on November 3, 2022, while Anti-VEGF agents have provided a favorable prognosis for nAMD, they are associated with a substantial financial burden for patients and the healthcare system, due to their high cost as well as the need for frequent repeat treatments and visits. Ranibizumab portal delivery system (RPDS) used in age-related macular degeneration with fixed 6-months refills over a one-year duration cost US$ 21,016. The monthly intravitreal injections of ranibizumab cost US$ 1943, aflibercept cost US$ 5702, and bevacizumab cost US$ 16,732. Such high cost of medication can restrain market growth.
To counterbalance this restraint, a reimbursement policies should be introduce to reduce overall cost of treatment.
Side effects of wet AMD treatment
Side effects of wet AMD treatment is expected to hamper the North America & Europe age-related macular degeneration therapeutics market growth. For instance, according to an article published in the Journal of Ophthalmic and Vision Research on October 25, 2021, there are various wet AMD medications that have a variety of side effects. Effects including retinal vasculitis, intraocular inflammation, concurrent vascular occlusion, nausea, vomiting, and permanent vision loss in individuals are anticipated. Few reported side effects like lenticular opacities, punctate keratitis, corneal abrasion, posterior capsule opacification, cataract, increased intraocular pressure, blepharitis, conjunctivitis, and iritis. This inhibits market expansion.
To counterbalance this restrain, more research should be carried out to reduce side effects associated with treatment.
North America and Europe Age-related Macular Degeneration Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients